Preventing perinatal transmission of HIV - Costs and effectiveness of a recommended intervention

Public Health Reports

Volumn 111, Issue 4, 1996, Pages 335-341

  Gorsky, Robin D ^a   Farnham, Paul G ^b,c   Straus, Walter L ^b   Caldwell, Blake ^b   Holtgrave, David R ^d   Simonds, R J ^b   Rogers, Martha F ^b   Guinan, Mary E ^b,e  

^a UNIVERSITY OF NEW HAMPSHIRE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NEWBORN INFECTION; PATIENT COUNSELING; PERINATAL PERIOD; PRIORITY JOURNAL; VIRUS TRANSMISSION;

AIDS SERODIAGNOSIS; COST SAVINGS; COST-BENEFIT ANALYSIS; COUNSELING; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MATERNAL HEALTH SERVICES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROGRAM EVALUATION; UNITED STATES;

EID: 0029840159     PISSN: 00333549     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Davis SF, Byers RH, Lindegren ML, Caldwell MB, Karon JM, Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 1995;274:952-5.
2. Update: AIDS among women - United States, 1994. MMWR 1995;44:81-4. [Erratum MMWR 1995;44:135].
3. Zidovudine for the prevention of HIV transmission from mother to infant. MMWR 1994;43:285-7.
4. Connor EM, Sperling RS, Gelber R, Kiseley P, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
5. Recommendations of the Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus. MMWR 1994;43(No.RR-11).
6. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR 1995:44(No.RR-7).
7. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993;270:474-8.
8. Hsia CD, Fleishman JA, East JA, Hellinger FJ. Pediatric HIV infection: Recent evidence on the use and costs of health services. Arch Ped Adol Med 1995;149:489-96.
9. Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of childbearing age for human immunodeficiency virus: a cost-benefit analysis. Arch Intern Med 1992;152:2229-37.
10. Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of childbearing age for human immunodeficiency virus: a model-based policy analysis. Mgt Sci 1993;39:72-92.
11. National Center for Health Statistics. Trends in pregnancies and pregnancy rates, United States, 1980-88. Monthly Vital Statistics Report 1992;41:1-11.
12. National Center for Health Statistics. Health, United States, 1992. Hyattsville, MD: U.S. Public Health Service, 1993.
13. CDC. Abortion surveillance - United States, 1990. MMWR 1993;42(SS-6):29-57.
14. Technical guidance on HIV counseling. MMWR 1993;42:11-17.
15. Doll LS, Kennedy MB, HIV counseling and testing: what is it and how well does it work? In Schochetman G, George JR, eds. AIDS Testing: a comprehensive guide to technical, medical, social, legal, and management issues. 2nd ed. New York: Springer-Verlag, 1994:302-9.
16. National HIV Serosurveillance Summary: update - 1993. Vol 3. Atlanta, GA: Centers for Diseases Control and Prevention, 1995.
17. Farnham PG, Gorsky RD, Holtgrave DR, Jones WK, Guinan ME. Counseling and testing for HIV prevention: costs, effects, and cost-effectiveness of more rapid screening tests. Public Health Rep 1996; 111:44-53.
18. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43 (No.RR-12):1-10.
19. Barnhart HX, Caldwell MB, Thomas PT, et al. Natural history of HIV disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics, In press.
20. Barbacci M, Repke JT, Chaisson RE. Routine prenatal screening for HIV infection. Lancet 1991;337:(8743)709-11.
21. Cozen W, Mascola L, Enguidanos R, et al. Screening for HIV and hepatitis B virus in Los Angeles County prenatal clinics: a demonstration project. J Acquir Immune Defic Syndr 1993;6:95-8.
22. Febo I, Scott G, Mitchell C, Diaz C. Assessment of the implementation of the recommendations for the use of zidovudine (ZDV) to reduce perinatal transmission of HIV-1. [Abstract #572] Abstracts of the 2nd Annual Conference on Human Retroviruses and Related Infections. Washington, DC, 1995.
23. Matheson PB, Abrams EJ, Thomas PA, Hernan MA, et al. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 1995;172:353-8.
24. Boyer PJ, Dillon M, Navale M, Deveikis A, et al. Factors predictive of maternal-fetal transmission of HIV-1: preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA 1994;271:1925-30.
25. Rugg DL, MacGowan RJ, Stark KA, Swanson NM. Evaluating the CDC program for HIV counseling and testing. Public Health Rep 1991;106:708-13.
26. Lewis R, Obrien JM, Ray DT, Sibai BM. The impact of initiating a human immunodeficiency virus screening program in an urban obstetric population. Am J Obstet Gynec 1995;173:1329-33.
27. Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA 1988;259:365-9.
28. Tengs T, Adams ME, Pliskin JS, et al. Five hundred life saving interventions and their cost-effectiveness. Risk Analysis 1995;15:369-90.